Physician profile
James E Jernigan
NPI 1871550079
$1,762.81
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $190 · 2021: $65.97 · 2024: $56.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $309.03 | 2019-2020 | |
| Amarin Pharma, INC. | $207.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $166.95 | 2019 | |
| Amgen INC. | $166.10 | 2019-2020 | |
| Lilly USA, LLC | $151.40 | 2019 | |
| Pfizer INC. | $146.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $120.77 | 2019 | |
| Abbvie INC. | $82.37 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.71 | 2019 | |
| Antares Pharma, INC. | $52.63 | 2019 | |
| Genentech USA, INC. | $48.87 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $39.66 | 2021 | |
| Astellas Pharma US INC | $39.13 | 2019 | |
| Glaxosmithkline, LLC. | $34.17 | 2019 | |
| Sanofi Pasteur INC. | $28.00 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.86 | 2019 | |
| Abbott Laboratories | $15.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.41 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.78 | 2019 | |
| Shire North American Group INC | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jernigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.